Jingjing Zhao

Prof. Jingjing Zhao


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in Epilepsy & Behavior
Verified
Journal Article
Closed access
XSXiaojing Shi
Xiaojing Shi
YWYuanyuan Wang
Yuanyuan Wang
YZYaoyao Zhang
Yaoyao Zhang
CSChanggeng Song
Changgeng Song
YJYongli Jiang
Yongli Jiang
WJWen Jiang
Wen Jiang

1 July 2019 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
XLXiuxiu Leng
Xiuxiu Leng
FYFang Yuan
Fang Yuan
JZJingjing Zhao
Jingjing Zhao
CSChanggeng Song
Changgeng Song
ZZZhihan Zhao
Zhihan Zhao
WJWen Jiang
Wen Jiang

20 December 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
XZXiao Zhang
Xiao Zhang
JZJingjing Zhao
Jingjing Zhao
ZSZhongqing SUN
Zhongqing SUN
WDWei Dong
Wei Dong
LYLi Yao
Li Yao
WJWen Jiang
Wen Jiang
Introduction Despite the implementation of mechanical thrombectomy, acute ischaemic stroke with large vessel occlusion (AIS-LVO) remains a significant health concern, characterised by substantial morbidity and mortality. Our trial aims to evaluate the efficacy and safety of minocycline in reducing infarct volume and improving functional outcomes in patients undergoing mechanical thrombectomy for anterior circulation AIS-LVO. Methods and analysis The MIST-A trial is a prospective, randomised, open-label, blinded-endpoint trial to be conducted across 12 medical centres. The study will enrol 180 adult patients who have experienced an anterior circulation AIS-LVO and have undergone mechanical thrombectomy. These patients will be randomly divided into two groups: one receiving minocycline in addition to standard care and the other receiving only standard care. The primary efficacy outcome is the change in infarct volume as measured by MRI, from baseline to day 5. The secondary efficacy outcomes include the incidence of intracerebral haemorrhage occurring within 24 hours and the clinical scores between the baseline and follow-up assessments. The primary outcome will be assessed using a mixed-effects model to determine the association between treatment and outcomes. Ethics and dissemination The study is approved by the Ethics Committee of Xijing Hospital (XJLL-KY20222186) and is registered at ClinicalTrials.gov (NCT05487417). This trial is estimated to end in the first quarter of 2025 and study findings are expected to be published in scientific journals that undergo peer review and also to be showcased at scientific conferences. Trial registration number NCT05487417.

28 March 2026 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
YZYingchi Zhang
Yingchi Zhang
JZJingjing Zhao
Jingjing Zhao
ZFZhirong Fan
Zhirong Fan
XWXiaomu Wang
Xiaomu Wang
XSXiaodan Shi
Xiaodan Shi
WJWen Jiang
Wen Jiang

9 October 2026 in Trials
Verified
Journal Article
Open access
PDF file
XZXin Zhang
Xin Zhang
WLWen Li
Wen Li
ZSZhongqing Sun
Zhongqing Sun
XWXiaomu Wang
Xiaomu Wang
CSChanggeng Song
Changgeng Song
WJWen Jiang
Wen Jiang
Introduction: The cerebellum plays a crucial role in cognitive processing and thus presents a promising therapeutic target for Alzheimer’s disease (AD). This trial aims to evaluate the efficacy and safety of long-term, neuronavigated cerebellar intermittent theta burst stimulation (iTBS) in patients with AD. Methods and analysis: The ACT-AD trial is a multicenter, randomized, double-blind, sham-controlled study involving 100 participants with mild-to-moderate AD across 4 centers in China. Participants will be randomized to receive either cerebellar iTBS or sham stimulation for 4 weeks (daily sessions), followed by 8 weeks of weekly maintenance sessions. The primary outcome is the change in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score from baseline to week 12. Secondary outcomes include additional clinical scales. Exploratory outcomes include electroencephalogram (EEG), blood biomarkers and magnetic resonance imaging (MRI). Statistical analysis will follow intention-to-treat principles using mixed models for repeated measures (MMRM). Discussion: The ACT-AD trial will assess the efficacy and safety of long-term, neuronavigated cerebellar iTBS in treating patients with mild-to-moderate AD. Trial registration: ClinicalTrials.gov, NCT06669182. Registered on 31 October 2024.